Vaccinex, Inc. (VCNX) stock
VCNXOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2024, quarter ended Dec 31, 2024Last filing: 10-K on Apr 15, 2025
$1.00−0.01 (-0.99%)
Close on Oct 19, 2026Market cap $3.22MP/E –Yield –
Vaccinex total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Vaccinex's total debt was $25.00K at Dec 31, 2024. For fiscal 2024 it was $25.00K, down 75.2% from the year before. The highest annual figure on record is $1.13M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $25.00K | -75.2% |
| FY2023 | Dec 31, 2023 | $101.00K | -42.3% |
| FY2022 | Dec 31, 2022 | $175.00K | -29.7% |
| FY2021 | Dec 31, 2021 | $249.00K | -78.0% |
| FY2020 | Dec 31, 2020 | $1.13M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $25.00K | -75.2% |
| Q3 FY2024 | Sep 30, 2024 | $44.00K | -63.0% |
| Q2 FY2024 | Jun 30, 2024 | $63.00K | -54.3% |
| Q1 FY2024 | Mar 31, 2024 | $82.00K | -47.8% |
| Q4 FY2023 | Dec 31, 2023 | $101.00K | -42.3% |
| Q3 FY2023 | Sep 30, 2023 | $119.00K | -38.3% |
| Q2 FY2023 | Jun 30, 2023 | $138.00K | -34.9% |
| Q1 FY2023 | Mar 31, 2023 | $157.00K | -31.7% |
| Q4 FY2022 | Dec 31, 2022 | $175.00K | -29.7% |
| Q3 FY2022 | Sep 30, 2022 | $193.00K | -83.0% |
| Q2 FY2022 | Jun 30, 2022 | $212.00K | -81.3% |
| Q1 FY2022 | Mar 31, 2022 | $230.00K | -79.7% |
| Q4 FY2021 | Dec 31, 2021 | $249.00K | -78.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.13M | 0.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.13M | 0.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.13M | – |
| Q4 FY2020 | Dec 31, 2020 | $1.13M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.13M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.13M | – |
See a number that looks wrong?